Starpharma secures A$15.6 million for VivaGel programme
This article was originally published in Scrip
Executive Summary
The Australian firm Starpharma has raised A$15.6 million ($14.5 million) to fund a clinical programme for its lead product, VivaGel, in bacterial vaginosis.